Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 383

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Open access
Abida, Wassim, Campbell, David, Patnaik, Akash, Shapiro, Jeremy D., Sautois, Brieuc, Vogelzang, Nicholas J., Voog, Eric G., Bryce, Alan H., McDermott, Ray, Ricci, Francesco, Rowe, Julie, Zhang, Jingsong, Piulats, Josep Maria, Fizazi, Karim, Merseburger, Axel S., Higano, Celestia S., Krieger, Laurence E., Ryan, Charles J., Feng, Felix Y., Simmons, Andrew D., Loehr, Andrea, Despain, Darrin, Dowson, Melanie, Green, Foad, Watkins, Simon P., Golsorkhi, Tony, Chowdhury, Simon · 2020 · Clinical Cancer Research

Abstract

Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations. Patients and Methods: TRITON2 enrolled patients who had progressed on one or two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Key endpoints were investigator-assessed radiographic response per modified RECIST/PCWG3 and PSA response (≥50% decrease from baseline). Results: TRITON2 enrolled 78 patients with a non-BRCA DDR gene alteration [ATM (n = 49), CDK12 (n = 15), CHEK2 (n = 12), and other DDR genes (n = 14)]. Among patients evaluable for each endpoint, radiographic and PSA responses were observed in a limited number of patients with an alteration in ATM [2/19 (10.5%) and 2/49 (4.1%), respectively], CDK12 [0/10 (0%) and 1/15 (6.7%), respectively], or CHEK2 [1/9 (11.1%) and 2/12 (16.7%), respectively], including no radiographic or PSA responses in 11 patients with confirmed biallelic ATM loss or 11 patients with ATM germline mutations. Responses were observed in patients with alterations in the DDR genes PALB2, FANCA, BRIP1, and RAD51B. Conclusions: In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2. However, patients with alterations in other DDR-associated genes (e.g., PALB2) may benefit from PARP inhibition. See related commentary by Sokolova et al., p. 2439

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-0394

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 383

Metadata

Authors
Abida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., Rowe, J., Zhang, J., Piulats, J. M., Fizazi, K., Merseburger, A. S., Higano, C. S., Krieger, L. E., Ryan, C. J., Feng, F. Y., Simmons, A. D., Loehr, A., Despain, D., Dowson, M., Green, F., Watkins, S. P., Golsorkhi, T., & Chowdhury, S.
Venue
Clinical Cancer Research
Published
2020-06-01
Volume
26
Issue
11
Pages
2487-2496
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3008060424
Cited by
383
References
23
FWCI
24.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-0394
The paper
Abida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., Rowe, J., Zhang, J., Piulats, J. M., Fizazi, K., Merseburger, A. S., Higano, C. S., Krieger, L. E., Ryan, C. J., Feng, F. Y., . . . Chowdhury, S. (2020). Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-0394

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.